Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feladilimab plus Pembrolizumab in R/M HNSCC
NCT04128696Phase 3Terminated
- Sponsor
- GSK
- Start
- Nov 2019
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Feladilimab + Pembrolizumab with Placebo + Pembrolizumab (2 arms). Primary endpoints: Overall Survival in PD-L1 CPS >=1 Population at 16 months, Overall Survival in PD-L1 CPS >=20 Population at 16 months and 1 more. Started Nov 2019; status: terminated.
02
Drugs
feladilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04128696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128696.